信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

盘前交易 08-05 04:14:09 EDT

4.38

+0.09

+2.10%

最高4.39	最低4.26	成交量18.10万
今开4.26	昨收4.29	日振幅3.03%
总市值2.10亿	流通市值1.53亿	总股本4,788万
成交额78.65万	换手率0.52%	流通股本3,499万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.38,"timestamp":1785873600000,"preClose":4.29,"halted":0,"volume":180955,"delay":0,"changeRate":0.020979020979020945,"floatShares":34989300,"shares":47884104,"eps":0.209971,"marketStatus":"盘前交易","change":0.09,"latestTime":"08-05 04:14:09 EDT","open":4.26,"high":4.39,"low":4.26,"amount":786458.65898,"amplitude":0.030303,"askPrice":4.94,"askSize":100,"bidPrice":1.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785936600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.38,"dividendRate":0.041096,"postHourTrading":{"tag":"盘后","latestPrice":4.38,"preClose":4.38,"latestTime":"19:53 EDT","volume":2250,"amount":9855.3005,"timestamp":1785887634831,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1213239628254101,"impliedVol":1.8138,"impliedVolPercentile":0.796},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2656589606","title":"歌礼制药-B早盘涨逾5% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589606","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656589606?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:55","pubTimestamp":1785812100,"startTime":"0","endTime":"0","summary":"8月3日，歌礼制药宣布，每日一次口服小分子GLP-1已获得美国食品药品监督管理局的III期临床研究批准。ASC30是歌礼口服小分子肥胖症治疗管线组合中的核心支柱。公司已针对ASC30长期体重管理适应症启动了一项全球III期临床项目，将在美国、欧洲和加拿大开展两项关键临床试验，将入组约4，600名肥胖或超重受试者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzv2245265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4590","GLP","BK1574","BK1515","BK4144","III","JDOC","BK1161","BK1191","01477","01672","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656032486","title":"复星医药(600196.SH)：恩格列净二甲双胍缓释片(III)获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656032486","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656032486?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:36","pubTimestamp":1785746171,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布公告，近日，公司控股子公司复星万邦(江苏)医药集团有限公司关于恩格列净二甲双胍缓释片(III)的药品注册申请获国家药品监督管理局批准。本次获批适应症为配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0060","BK1593","BK0183","BK0188","BK4134","BK0196","BK1191","BK0028","BK1515","600196","BK0012","BK0175","BK0239","02196","BK0096","III","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655836775","title":"信息服务业增势良好 广东两业协同发展更有支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2655836775","media":"金羊网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655836775?lang=zh_cn&edition=full","pubTime":"2026-07-29 07:02","pubTimestamp":1785279720,"startTime":"0","endTime":"0","summary":"信息服务业保持较快增长，进一步增强了广东经济平稳运行的支撑力量。面向下一步，广东仍需加强基础软件、工业软件等关键领域研发，培育更具竞争力的信息服务企业，将数智技术转化为解决实际生产问题的专业能力，为广东推动制造业与服务业协同发展增添力量，为经济稳中提质注入更多活力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-07-29/doc-inikmivv5984205.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-07-29/doc-inikmivv5984205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654100808","title":"翰森制药(03692)：HS-20093治疗骨肉瘤III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654100808","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654100808?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:01","pubTimestamp":1785232902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 公布，该集团自研B7-H3靶向抗体-药物偶联物HS-20093，在用于既往接受过至少二线系统治疗后进展或复发的骨肉瘤患者的关键性III期临床试验中达到主要终点。安全性特征与既往研究结果一致，未发现新的安全性信号。ARTEMIS-011研究详细数据预计未来在国际肿瘤学术大会上予以公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1191","03692","BK1589","BK1583","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071182","title":"港股异动 | 乐普生物(02157)涨近4% CMG901全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654071182?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:28","pubTimestamp":1785223688,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物涨近4%，早盘曾涨逾12%。截至发稿，涨3.83%，报4.61港元，成交额9164.84万港元。消息面上，7月28日，乐普生物发布公告，有关集团与AstraZeneca AB就抗体偶联药物候选药物CMG901合作的最新情况。截至本公告日期，CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，sonesitatug vedotin在二线及后线(2L+) Claudin 18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","III","BK4588","BK4585","BMED","IBBQ","KCAI","BK1161","VXUS","BK4134","MDTX","02157","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654127078","title":"乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654127078","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654127078?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:32","pubTimestamp":1785213120,"startTime":"0","endTime":"0","summary":"【乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点】乐普生物（02157.HK）发布自愿公告，公告基本信息：公司于2026年7月28日发布自愿性公告，披露其与阿斯利康合作开发的抗体偶联药物CMG901（sonesitatugvedotin，AZD0901）全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823312261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823312261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4134","III","02157","IBBQ","PSYK","IBBJ","BK1161","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020773","title":"康诺亚-B：CMG901全球III期临床获积极顶线结果，OS改善具统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020773","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654020773?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:01","pubTimestamp":1785211290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043933","title":"石药集团：盐酸阿姆西汀肠溶片III期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043933","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654043933?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:15","pubTimestamp":1785158100,"startTime":"0","endTime":"0","summary":"石药集团：盐酸阿姆西汀肠溶片III期临床试验达主要终点","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822364345.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822364345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1226288170.HKD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0140636845.USD","LU0326950275.SGD","MDTX","01093","LU1328277881.USD","IE0008368742.USD","III","IE00BZ08YR35.GBP","LU0072913022.USD","PSYK","IBBQ","LU1226287792.SGD","LU0315179316.USD","HK0000165453.HKD","LU1813983027.USD","LU1993786604.SGD","IBBJ","LU0067412154.USD","LU1152091754.HKD","LU2039709279.SGD","LU0501845795.SGD","IE0008369823.USD","BK1191","LU1226287529.USD","LU1226287875.USD","BK1521","LU0314109678.HKD","LU1008478684.HKD","LU1807302812.USD","KURE","SG9999004220.SGD","LU0880133367.SGD","LU1226288253.USD","BMED","LU1152091168.USD","LU1951186391.HKD","BK4134","IE00B543WZ88.USD","BK1515","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654385043","title":"Arrowhead完成Zodasiran全球III期YOSEMITE试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654385043","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654385043?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:14","pubTimestamp":1785158040,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals今日宣布，其针对Zodasiran的全球III期YOSEMITE临床试验已完成患者入组。YOSEMITE试验最初计划招募60名受试者，但基于全球范围内HoFH患者与医生的强烈响应，最终入组人数增至70人。此前的II期GATEWAY研究显示，Zodasiran在HoFH患者中带来了具有临床意义的LDL-C水平降低，且安全性良好，未出现药物相关严重不良事件或死亡。Arrowhead预计该研究将于2027年中期完成，若结果积极，计划随后在多个地区提交监管审批申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhcmc0729606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048711","title":"阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048711","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654048711?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:06","pubTimestamp":1785157560,"startTime":"0","endTime":"0","summary":"阿斯利康今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhckx3037081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0310800379.SGD","LU2462157665.USD","LU2236285917.USD","LU2237443549.SGD","LU0889565916.HKD","LU2237443895.HKD","LU2237443978.SGD","AZNH","LU2468319806.SGD","LU2237443382.USD","LU2237443465.HKD","LU2237443622.USD","LU2456880835.USD","LU2417539215.USD","BK4568","BK4134","LU0289739699.SGD","AZN","LU1267930573.SGD","LU2089984988.USD","LU0708994859.HKD","III","LU1829250122.USD","LU0320765992.SGD","BK4585","LU0029864427.USD","LU0432979614.USD","LU0058720904.USD","LU0128525929.USD","BK4588","IE00B3T34201.USD","LU0109394709.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654683048","title":"石药集团：盐酸阿姆西汀肠溶片III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654683048","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654683048?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:59","pubTimestamp":1785157151,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","BMED","IBBQ","IBBJ","PSYK","MDTX","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654169740","title":"诺诚健华：ICP-488治疗银屑病III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654169740","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654169740?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:34","pubTimestamp":1785144840,"startTime":"0","endTime":"0","summary":"南财智讯7月27日电，诺诚健华（09969.HK）发布自愿公告，公司自主研发的TYK2变构抑制剂fadeucravacinib（ICP-488）用于治疗中重度斑块状银屑病的III期注册性临床试验成功达到主要终点，统计学显著且具临床意义，并同步达成多项次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822201140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822201140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK1161","BK4134","688428","BK0239","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013011","title":"恒瑞医药：子公司HRS-1780片获批开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013011","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013011?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:53","pubTimestamp":1785142380,"startTime":"0","endTime":"0","summary":"7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III期临床试验。HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822155717.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822155717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","LU2580892789.USD","LU1781817850.SGD","LU2097828474.EUR","LU0359202008.SGD","600276","LU2148510915.USD","BK0183","LU0405327148.USD","BK0060","LU2495084118.USD","BK4134","LU1997245177.USD","LU1328615791.USD","LU1997245094.SGD","LU2328871848.SGD","LU1064131003.USD","BK1191","LU0405327494.USD","LU1146622755.USD","LU1580142542.USD","LU1655091616.SGD","LU2580892862.HKD","PSYK","BK0188","LU2097828805.USD","LU2097828714.EUR","LU0359201885.HKD","LU1064130708.USD","LU1023057109.AUD","LU1255011170.USD","01276","LU2543165471.USD","IBBQ","LU1997244956.HKD","LU1969619763.USD","III","LU2097828631.EUR","LU2488822045.USD","BK0196","BK0028","LU2097828557.USD","BK0012","LU1820825898.SGD","LU0359201612.USD","BK0239","LU2289578879.USD","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653403937","title":"百利天恒：伦康依隆妥单抗两项III期临床完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653403937","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653403937?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"7月23日，百利天恒（688506）发布公告，公司自主研发的全球首创EGFR×HER3双抗ADC伦康依隆妥单抗/宜泽康（BL-B01D1/iza-bren）两项III期临床试验于近日分别完成首例受试者入组，涉及适应症为经内分泌治疗失败的晚期HR+HER2-乳腺癌和含铂化疗失败的局部晚期或转移性胆道癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819152061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233819152061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","02615","688506","BK0239","BK4134","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百济神州/安进 FIC 双抗，皮下制剂进入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653074709?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0588546209.SGD","LU2242652126.USD","LU2468319806.SGD","LU1061106388.HKD","KURE","LU2242646821.SGD","LU1571399168.USD","LU0868494617.USD","TBXU","LU1969619763.USD","ONC","BIB","BK4534","LU0289739699.SGD","BK4585","BK4581","SG9999001440.SGD","BK1588","688235","BK4139","III","LU0889565916.HKD","LU2328871848.SGD","IE0009355771.USD","LU1770034418.SGD","06160","BK1583","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4134","PBE","LU0058720904.USD","LU0320765992.SGD","BBH","LU1251922891.USD","IBB","LU0122379950.USD","LU2112291526.USD","BK1500","AMGN","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4599","BK4588","PJP","IE0002141913.USD","LU0307460666.USD","LU1719994722.HKD","IBBQ","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744496","title":"百利天恒：伦康依隆妥单抗III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653744496?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:16","pubTimestamp":1784805390,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BK4134","BMED","MDTX","III","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653187205","title":"Devonian获加拿大卫生部批准，启动Thykamine小儿特应性皮炎II/III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2653187205","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653187205?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:21","pubTimestamp":1784643660,"startTime":"0","endTime":"0","summary":"Devonian Health Group7月21日宣布，已获得加拿大卫生部的临床试验申请授权，将启动PUR 0110乳膏治疗小儿轻中度特应性皮炎的II/III期临床研究。此次儿科项目基于此前成人II期试验取得的积极结果，该结果已发表于同行评议期刊《Journal of Drugs in Dermatology》，显示Thykamine乳膏在成人轻中度特应性皮炎中具有统计学显著的疗效和良好的安全性。特应性皮炎是全球最常见的儿童慢性炎症皮肤病之一，约60%患儿在一岁内发病，85%在五岁前患病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqvau9122982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272674","title":"君实生物：特瑞普利单抗新适应症补充申请获受理 拓展至II-III期可切除非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272674","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653272674?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:42","pubTimestamp":1784634120,"startTime":"0","endTime":"0","summary":"7月21日，君实生物（688180/01877）发布公告，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗联合含铂化疗围手术期治疗可切除II-III期非小细胞肺癌的补充申请获得受理。本次申请的适应症由可切除IIIA-IIIB期非小细胞肺癌扩展为可切除II-III期非小细胞肺癌。由于药品研发周期长，审批环节多，本次补充申请能否获得批准存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213815805376.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815805376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1515","III","BK1161","BK1583","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652688822","title":"加科思-B(01167)：完成泛KRAS抑制剂JAB-23E73联合化疗用于KRAS突变胰腺癌一线 治疗之Ib/III期临床试验在中国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652688822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652688822?lang=zh_cn&edition=full","pubTime":"2026-07-20 06:42","pubTimestamp":1784500970,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B 发布公告，本公司的泛KRAS抑制剂JAB-23E73联合白蛋白结合型紫杉醇及吉西他滨用于KRAS突变胰腺癌一线治疗之Ib/III期临床试验在中国完成首例患者给药。本项研究的启动依托此前公布在本公司2025年度年度报告中并仍在推进的I期临床试验所取得的喜人初步临床数据。KRAS突变在胰腺癌中发生率极高。本项研究正式启动，是JAB-23E73研发进程中的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4134","BK1161","IBBQ","01167","III","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651442713","title":"中国电信云网发展部和政企信息服务事业群总经理调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2651442713","media":"人民邮电报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651442713?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:57","pubTimestamp":1784206620,"startTime":"0","endTime":"0","summary":"记者获悉，潘天舒任中国电信集团有限公司云网发展部（国际部）总经理。潘天舒曾任中国电信集团有限公司政企信息服务事业群总经理。董涛任中国电信集团有限公司政企信息服务事业群总经理。董涛曾任中国电信广西分公司总经理、中国电信江苏分公司总经理、中国电信集团有限公司云网发展部（国际部）总经理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163809284186.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809284186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0039217434.USD","BK1506","HK0000286598.CNH","BK1536","BK0261","00728","HK0000288784.HKD","BK4134","BK1589","BK1610","HK0000288743.USD","601728","HK0000352291.HKD","BK1133","SGXZ49509284.SGD","III","SGXZ81163826.USD","HK0000352382.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0554},{"period":"1month","weight":0.0657},{"period":"3month","weight":0.058},{"period":"6month","weight":-0.1412},{"period":"1year","weight":0.021},{"period":"ytd","weight":-0.2422}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.021525},{"month":6,"riseRate":0.473684,"avgChangeRate":0.009959},{"month":7,"riseRate":0.473684,"avgChangeRate":0.014159},{"month":8,"riseRate":0.578947,"avgChangeRate":0.012712},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}